NCT01224288Active, not recruitingPhase 3
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Companion to Protocol 2010-0085
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
This is a companion protocol to MD Anderson Cancer Center study 2010-0085 (Sequential Therapy in Advanced Renal Cell Carcinoma Therapy: The "START" Trial). The goal of this clinical research study is to learn if dynamic contrast enhanced computed tomography (DCE-CT) scans can help researchers learn if the study drug received as part of study 2010-0085 (either everolimus, bevacizumab, or pazopanib) is working.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 18 Oct 2010
- Start date
- Jan 2011
- Primary completion date
- Apr 2029
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Kidney cancer
- NCT number
- NCT01224288
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 120
- From Jan 2011 to the primary completion date, Apr 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Radiotherapy: Subjects may not have received prior radiotherapy to the index lesion within 4 weeks
Other illness
- Allergy to CT contrast media requiring the administration of steroid prophylaxis.
Lab values
- Female subjects of childbearing potential (unless they have a negative serum or urine pregnancy test within 3 days prior to start of study treatment).
Other
- Female subjects who are pregnant or lactating.
Who the study is looking for
- Patient must be enrolled or being considered for enrollment on protocol 2010-0085.
- Patients must have metastatic renal cell carcinoma (RCC).
- Age \>/= 18 years.
- Subjects must have adequate renal function as defined by serum creatinine \< 1.5x upper limit of normal.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Texas - MD Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.